Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | Emerging monoclonal antibodies for lymphoma therapy

Thomas Kipps • 12 Nov 2015
iwNHL 2015
Non-Hodgkin Lymphoma Antibodies Ibrutinib Obinutuzumab Ofatumumab Rituximab Venetoclax

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Thomas J. Kipps, MD, PhD, of the University of California, San Diego, San Diego, CA, discusses novel monoclonal antibodies against CD20, including rituximab, ofatumumab and obinutuzumab, that are progressing in clinical development as single agents and in combination for the treatment of patients with non-Hodgkin lymphoma.

More from Thomas Kipps

1:28
A long-term analysis of lenalidomide and rituximab for the treatment of CLL
Thomas Kipps • 11 Dec 2023
1:35
Ven-based regimens for R/R CLL and considering an MRD-guided strategy
Thomas Kipps • 11 Dec 2023
1:18
The use of genomics to help select treatment in CLL
Thomas Kipps • 9 Jun 2023
2:12
Understanding and overcoming resistance to BTK and BCL-2 inhibitors in CLL
Thomas Kipps • 9 Jun 2023

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals